The global biotechnology instruments market size was estimated at USD 86.28 billion in 2022 and is expected to grow at a compound annual growth rate (CAGR) of 3.94% from 2023 to 2030. The growing adoption of precision medicine, growing knowledge of molecular biologics & genomics, and rising demand for spectroscopy techniques for drug development are a few of the factors that are anticipated to fuel the growth of the market. In addition, the increasing prevalence of chronic conditions, including diseases like COVID-19, cardiovascular disorders, diabetes, cancer, and others, is anticipated to drive the market growth. The pandemic impacted the market significantly due to the rise in demand for vaccine development and diagnostics, causing disruptions in supply chains & laboratory access, accelerating the adoption of automation and data analysis techniques.
Researchers and scientists from various laboratories are using nanopore sequencing, which is anticipated to facilitate the rapid allocation of sequence data from COVID-19. Researchers have been sharing sequenced genomes on public databases, including GenBank and GISAID, to analyze public health responses. Due to the high number of cases, laboratories have built the capacity to sequence genomes from a large number of samples. Owing to these efforts, sequencing data of a wide range of samples are available in public databases. In April 2023, scientists and researchers developed a mobile printer that is used for producing thumbnail-sized patches, which delivers mRNA COVID-19 vaccines.
This device aims to utilize the tabletop device to immunize individuals in remote areas. Due to the growing number of COVID-19 cases, companies offered their expertise in nucleic acid purification, collaborative technical assistance, amplification solutions, and labeling technologies. These technologies are anticipated to simplify the workflow and accelerate the work of researchers engaged in the development of vaccines during pandemics, such as COVID-19. For instance, in April 2023, Mawi DNA Technologies, a biotech company, was granted by the FDA for the clearance of the iSWAB-RC-EL collection device. These devices are used for stabilizing and deactivating human upper respiratory and saliva samples potentially containing SARS-CoV-2.
In January 2023, Qiagen announced the launch of the EZ2 Connect MDx IVD platform to offer automated sampling for diagnostic labs. The device allows labs to simultaneously purify RNA and DNA from up to 24 samples within 30 minutes. Thus, the launch of various technologies is anticipated to impel the growth of the market over the forecast period. Moreover, in June 2023, Waters and Sartorius, manufacturers of instruments and software, collaborated to provide integrated process analytics for chromatography columns. This partnership was built upon their existing alliance, which now extends from upstream to encompass downstream analytics.
In August 2023, Thermo Fisher Scientific introduced a new chromosomal microarray aimed at enhancing productivity, efficiency, and profitability in cytogenetic research labs. The array sets a new standard with a two-day turnaround time. Catering to prenatal, postnatal, and oncology research, the Applied Biosystems CytoScan HD Accel array comprehensively examines the entire human genome and offers enhanced coverage across over 5,000 vital genome regions, delivering insights into chromosomal variations. Thus, such collaboration and partnership activities are anticipated to propel the growth of the global market over the forecast period.
On the basis of product, the analytical instruments segment accounted for the largest market share of 61.92% in 2022. These instruments, encompassing technologies, such as mass spectrometry, chromatography, and spectroscopy, play a crucial role in enabling precise analysis and characterization of biological samples, supporting applications ranging from drug discovery to genetic research. Their widespread utilization underscores their significance in driving advancements within the biotechnology industry, contributing significantly to research, development, and innovation. In March 2023, Illumina Inc., a U.S.-based global DNA sequencing and array-based technologies collaborated with the French company, GenoScreen, to introduce a package that integrates Illumina products with the GenoScreen Deeplex Myc-TB assay.
This assay utilizes targeted next-generation sequencing (NGS) to swiftly and comprehensively identify drug resistance in cases of tuberculosis. Thus, such collaborative initiatives are anticipated to boost the growth of the segment over the forecast period. The cell culture instruments segment is expected to grow at the fastest CAGR of 9.98% from 2023 to 2030. These instruments including bioreactors, incubators, and culture media, are facilitating the growth and manipulation of cells for various applications, including drug development, tissue engineering, and regenerative medicine.
The increasing demand for personalized medicine and the growing significance of cell-based therapies are driving the expansion of this sector, making cell culture instruments a key driver of innovation and progress in the biotechnology industry. In May 2023, HiMedia Laboratories, a Mumbai-based firm, and Advanced Instruments, a U.S.-based firm, collaborated to introduce their newest advancement in microbiology research: the Anoxomat III Anaerobic Culture System. Thus, such strategic initiatives are expected to propel the growth of cell culture instruments from 2023 to 2030.
On the basis of end-use, the pharmaceutical & biotechnology companies segment dominated the market with a revenue share of 38.10% in 2022. These industries heavily rely on a diverse range of instruments, such as gene sequencers, protein analyzers, and high-throughput screening systems, to drive drug discovery, development, and production processes. The relentless pursuit of novel therapies, precision medicine, and advanced research methods continues to fuel the demand for cutting-edge biotechnology instruments, solidifying their pivotal role in shaping the trajectory of scientific and medical advancements.
The academic & research institutions segment is expected to grow at the fastest CAGR of 5.07% from 2023 to 2030. Various academic & research institutions and laboratories are increasingly adopting a wide array of biotechnology instruments, such as DNA synthesizers, flow cytometers, and microarray systems. This growth is driven by a surge in interdisciplinary research, collaborations, and the pursuit of breakthrough discoveries across fields like genomics, proteomics, and synthetic biology. The research activities are expected to emphasize innovation, and the generation of fundamental knowledge positions academic & research institutions as key contributors to the dynamic evolution of biotechnology instrument technologies. Thus, this is anticipated to speed up drug research & development, as well as bring significant advancements to the field.
North America held the largest share of 43.95% of the global market in 2022 due to the high demand and affordability of biotechnology instruments. Growth in R&D efforts and growing public-private investments in research also strengthen demand, contributing to market growth. For instance, in August 2023, the U.S. Department of Health and Human Services through the Administration for Strategic Preparedness and Response was funded with over USD 1.4 billion for Project NextGen. This initiative aims to foster the creation of advanced tools and technologies that would provide long-term protection against COVID-19.
Thus, continuous advancements and growing government investments in biotechnology instruments, coupled with the affordable adoption of innovative systems solidify the U.S. as the world's most lucrative market. The regional market in Asia Pacific is anticipated to register the fastest growth rate of 5.36% from 2023 to 2030. This trend is mainly due to the rapid growth of the biotechnology sectors in emerging economies like China and India. Robust government backing for biotechnology in these nations also fuels market expansion. Continuous R&D investments further boost demand for biotechnology instruments.
For instance, in March 2023, the Australian government announced an investment of USD 400 million, which would support medical research projects, including projects to improve First Nation Health. In August 2023, the Indian government announced a new Anusandhan National Research Foundation (ANRF), which would empower the nation's scientists to play a pivotal role in tackling worldwide challenges. The government plans to allocate a budget of ₹500 billion (USD 6.05 billion) to the ANRF for the period spanning 2023 to 2028. Hence, increasing research spending and growing government investments are anticipated to propel the market growth in the Asia Pacific region.
Market leaders are involved in extensive R&D for manufacturing cost-efficient and technologically advanced products. Several strategies, such as mergers & acquisitions, undertaken by these organizations to expand their market presence are anticipated to create significant growth opportunities over the forecast period. For instance, in August 2023, Roche announced the launch of a novel addition to the Cobas connection modules (CCM), the CCM Vertical, which would enhance the efficiency of the laboratory. Such strategic initiatives by organizations are anticipated to propel the growth of the market. Some of the key players operating in the global biotechnology instruments market include:
Thermo Fisher Scientific, Inc.
Waters Corp.
Shimadzu Corp.
Danaher
Agilent Technologies, Inc.
Bruker Corp.
PerkinElmer, Inc.
Mettler Toledo
Zeiss Group
Bio-Rad Laboratories, Inc.
Illumina, Inc.
Eppendorf SE
F. Hoffmann-La Roche AG
Sartorius AG
Avantor, Inc.
Report Attribute |
Details |
Market size value in 2023 |
USD 89.05 billion |
Revenue forecast in 2030 |
USD 116.68 billion |
Growth rate |
CAGR of 3.94% from 2023 to 2030 |
Base year for estimation |
2022 |
Historical data |
2018 - 2021 |
Forecast period |
2023 - 2030 |
Report updated |
September 2023 |
Quantitative units |
Revenue in USD million/billion and CAGR from 2023 to 2030 |
Report coverage |
Revenue forecast, company ranking, competitive landscape, growth factors, and trends |
Segments covered |
Product, end-use, region |
Regional scope |
North America; Europe; Asia Pacific; Latin America; MEA |
Country scope |
U.S.; Canada; UK; Germany; France; Italy; Spain; Norway; Sweden; Denmark; Japan; China; India; Australia; South Korea; Thailand; Brazil; Mexico; Argentina; South Africa; Saudi Arabia; UAE; Kuwait |
Thermo Fisher Scientific, Inc.; Waters Corp.; Shimadzu Corp.; Danaher; Agilent Technologies, Inc.; Bruker Corp.; PerkinElmer, Inc.; Mettler Toledo; Zeiss Group; Bio-Rad Laboratories, Inc.; Illumina, Inc.; Eppendorf SE; F. Hoffmann-La Roche AG; Sartorius AG; Avantor, Inc. |
|
Customization scope |
Free report customization (equivalent up to 8 analysts’ working days) with purchase. Addition or alteration to country, regional & segment scope |
Pricing and purchase options |
Avail customized purchase options to meet your exact research needs. Explore purchase options |
This report forecasts revenue growth and provides an analysis of the latest trends in each of the sub-segments from 2018 to 2030. For this study, Grand View Research has segmented the biotechnology instruments market report based on product, end-use, and region:
Product Outlook (Revenue, USD Million, 2018 - 2030)
Analytical Instruments
Polymerase Chain Reaction
Spectroscopy
Microscopy
Chromatography
Flow Cytometry
Sequencing
Microarray
Others
Cell Culture Instruments
Culture Systems
Incubators
Cryostorage Equipment
Biosafety Equipment
Pipetting Instruments
Cell Separation Instruments
Centrifuge
Filtration Systems
Magnetic-activated Cell Separator Systems
Immunoassay Instruments
Clinical Chemistry Analyzers
Others
End-use Outlook (Revenue, USD Million, 2018 - 2030)
Pharmaceutical & Biotechnology Companies
Hospitals & Diagnostic Laboratories
Academic & Research Institutes
Others
Regional Outlook (Revenue, USD Million, 2018 - 2030)
North America
U.S.
Canada
Europe
UK
Germany
France
Italy
Spain
Denmark
Sweden
Norway
Asia Pacific
Japan
China
India
Australia
South Korea
Thailand
Latin America
Brazil
Mexico
Argentina
Middle East & Africa
South Africa
Saudi Arabia
UAE
Kuwait
b. Analytical instruments dominated the biotechnology instruments market with a share of over 61% in 2022. This is attributable to advancements in technologies such as PCR, mass spectrometry, and chromatography, along with the increased adoption of analytical instruments.
b. Some key players operating in the biotechnology instruments market include Thermo Fisher Scientific, Inc., Waters Corp., Shimadzu Corp., Danaher, Agilent Technologies, Inc., Bruker Corp., PerkinElmer, Inc., Mettler Toledo, Zeiss Group, Bio-Rad Laboratories, Inc., Illumina, Inc., Eppendorf SE, F. Hoffmann-La Roche AG, Sartorius AG, and Avantor, Inc.
b. Key factors that are driving the biotechnology instruments market growth include increasing demand for analytical instruments, growing prevalence of target diseases and rising geriatric population, and technological advancements in research-use instruments.
b. The global biotechnology instruments market size was estimated at USD 86.28 billion in 2022 and is expected to reach USD 89.05 billion in 2023.
b. The global biotechnology instruments market is expected to grow at a compound annual growth rate of 3.94% from 2023 to 2030 to reach USD 116.68 billion by 2030.
NEED A CUSTOM REPORT?
We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports, as well as offer affordable discounts for start-ups & universities. Contact us now
We are GDPR and CCPA compliant! Your transaction & personal information is safe and secure. For more details, please read our privacy policy.
"The quality of research they have done for us has been excellent."